Venous infers: Early work sufficient to attract $21M for Ilkos' leg ulcers effort

"The beauty of this deal is that it's not just an out-licensing deal from Servier," CTI Life Sciences partner Jean-François Leprince told BioWorld Today as he explained newly formed Ilkos Therapeutics Inc., which made its debut with a $21 million three-way investment.